Abstract 2174: A comprehensive CRISPR/Cas9-based RAS knock-in cell line platform (50+ models) for assessing efficacy of KRAS-targeted inhibitors in RAS-mutant malignancies.
Year: 2026
Type: conference-abstract
Source: Cancer Research
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7148680841
Cites:
Cited by:
Related to: